PharVision Advisers’s Materion MTRN Stock Holding History

PharVision Advisers’s Portfolio MTRN Stock Details MTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,488	Closed	-$301K	–	895
2025 Q3	$301K	Buy	+2,488	New	+$261K	0.17%	225

Other funds holding MTRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

PharVision Advisers's MTRN Position: Q4 2025 in Review

PharVision Advisers sold out of Materion (MTRN) in Q4 2025, closing a stake of 2,488 shares — an estimated $301K sold.

PharVision Advisers first reported a position in MTRN in Q3 2025 and held it in 1 quarter. The position peaked at $301K in Q3 2025. 297 funds tracked by Wall St. Rank hold MTRN as of Q4 2025.

PharVision Advisers reported no remaining Materion position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 2,488 Materion shares in Q4 2025, an estimated $301K.
PharVision Advisers first reported a position in Materion in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Materion position peaked at $301K in Q3 2025.
297 funds tracked by Wall St. Rank held Materion as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.